Транскатетерное эндопротезирование клапана аорты

  • Авторы: Семитко С.П1
  • Учреждения:
    1. ГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава РФ, Москва
  • Выпуск: Том 15, № 1 (2013)
  • Страницы: 81-86
  • Раздел: Статьи
  • URL: https://journal-vniispk.ru/2075-1753/article/view/93803
  • ID: 93803

Цитировать

Полный текст

Об авторах

С. П Семитко

ГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава РФ, Москва

Кафедра рентгенхирургических методов диагностики и лечения

Список литературы

  1. Davies H. Catheter mounted valve for temporary relief of aortic insufficiency. Lancet 1965; 1.
  2. Moulopoulos S.D., Anthopoulos L, Stamatelopoulos S, Stefadouros M. Catheter - mounted aortic valves. Ann Thorac Surg 1971; 11: 423–30.
  3. Phillips S.J., Ciborski M, Freed P.S. et al. A temporary catheter - tip aortic valve: hemodynamic effects on experimental acute aortic insufficiency. Ann Thorac Surg 1976; 21: 134–7.
  4. Matsubara T, Yamazoe M, Tamura Y et al. Balloon catheter with check valves for experimental relief of acute aortic regurgitation. Am Heart J 1992; 124: 1002–8.
  5. Cribier A, Savin T, Saoudi N et al. Percutaneous transluminal valvuloplasty of acquired aortic stenosis in elderly patients: an alternative to valve replacement? Lancet 1986; 1: 63–7.
  6. Drobinski G, Lechat P, Metzger J.P. et al. Results of percutaneous catheter valvuloplasty for calcified aortic stenosis in the elderly. Eur Heart J 1987; 8: 322–8.
  7. Otto C.M., Mickel M.C., Kennedy J.W. et al. Three - year outcome after balloon aortic valvuloplasty. Insights into prognosis of valvular aortic stenosis. Circulation 1994; 89: 642–50.
  8. Cribier A, Eltchaninoff H, Bash A et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation 2002; 106: 3006–8.
  9. Cribier A, Eltchaninoff H, Tron C et al. Treatment of calcific aortic stenosis with the percutaneous heart valve: mid - term follow - up from the initial feasibility studies: the French experience. J Am Coll Cardiol 2006; 47: 1214–23.
  10. Webb J.G., Chandavimol M, Thompson C.R. et al. Percutaneous aortic valve implantation retrograde from the femoral artery. Circulation 2006; 113: 842–50.
  11. De Jaegere P, van Dijk L.C., Laborde J.C. et al. True percutaneous implantation of the Core Valve aortic valve prosthesis by the combined use of ultrasound guided vascular access, Prostar XL and the Tandem Heart. EuroIntervention 2007; 2: 500–5.
  12. O’Brien S.M., Shahian D.M., Filardo G et al. Society of Thoracic Surgeons Quality Measurement Task Force. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 2-isolated valve surgery. Ann Thorac Surg 2009; 88: S23–42.
  13. Nashef S.A., Roques F, Michel P et al. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg 1999; 16: 9–13.
  14. Buellesfeld L, Gerckens U, Schuler G et al. 2-year follow - up of patients undergoing transcatheter aortic valve implantation using a self - expanding valve prosthesis. J Am Coll Cardiol 2011; 57: 1650–7.
  15. Delgado V, Ewe S.H., Ng A.C. et al. Multimodality imaging in transcatheter aortic valve implantation: key steps to assess procedural feasibility. EuroIntervention 2010; 6: 643–52.
  16. Piazza N, de Jaegere P, Manoharan G et al. Patient Selection for the CoreValve ReValving System. In: Serruys P, Piazza N, Cribier A et al. Transcatheter aortic valve implantation: Tips and tricks to avoid failure. New York: Informa Healthcare 2011; 82.
  17. Piazza N, Serruys P.W., Lange R. Getting safely in and out of a transcatheter aortic valve implantation procedure vascular complications according to the valvular academic research consortium criteria. JACC Cardiovasc Interv 2011; 4: 859–60.
  18. Petronio A.S., de Carlo M, Bedogni F et al. Safety and efficacy of the subclavian approach for transcatheter aortic valve implantation with the CoreValve revalving system. Circ Cardiovasc Interv 2010; 3: 359–66.
  19. Guarracino F, Covello R.D., Landoni G et al. Anesthetic management of transcatheter aortic valve implantation with transaxillary approach. J Cardiothorac Vasc Anesth 2011; 25: 437–43.
  20. Kempfert J, Rastan A, Holzhey D et al. Transapical aortic valve implantation: analysis of risk factors and learning experience in 299 patients. Circulation 2011; 124: S124–9.
  21. Kempfert J, Rastan A.J., Mohr F.W., Walther T. A new self - expanding transcatheter aortic valve for transapical implantation – first in man implantation of the JenaValve. Eur J Cardiothorac Surg 2011; 40: 761–3.
  22. Bapat V, Thomas M, Hancock J, Wilson K. First successful trans - catheter aortic valve implantation through ascending aorta using Edwards SAPIEN THV system. Eur J Cardiothorac Surg 2010; 38: 811–3.
  23. Cockburn J, Trivedi U, Hildick-Smith D. Transaortic transcatheter aortic valve implantation within a previous bioprosthetic aortic valve replacement. Catheter Cardiovasc Interv 2011; 78: 479–84.
  24. Piazza N, de Jaegere P, Schultz C et al. Anatomy of the aortic valvar complex and its implications for transcatheter implantation of the aortic valve. Circ Cardiovasc Interv 2008; 1: 74–81.
  25. Schultz C.J., Moelker A, Piazza N et al. Three dimensional evaluation of the aortic annulus using multislice computer tomography: are manufacturer’s guidelines for sizing for percutaneous aortic valve replacement helpful? Eur Heart J 2009.
  26. Tops L.F., Wood D.A., Delgado V et al. Noninvasive evaluation of the aortic root with multislice computed tomography implications for transcatheter aortic valve replacement. JACC Cardiovasc Imaging 2008; 1: 321–30.
  27. Ng A.C., Yiu K.H., Ewe S.H. et al. Influence of left ventricular geometry and function on aortic annular dimensions as assessed with multi - detector row computed tomography: implications for transcatheter aortic valve implantation. Eur Heart J 2011; 32: 2806–13.
  28. Schultz C, Moelker A, Tzikas A et al. The use of MSCT for the evaluation of the aortic root before transcutaneous aortic valve implantation: the Rotterdam approach. EuroIntervention 2010; 6: 505–11.
  29. Schultz C.J., Moelker A.D., Tzikas A et al. Cardiac CT: necessary for precise sizing for transcatheter aortic implantation. EuroIntervention 2010; (6 Suppl. G): G6–G13.
  30. Nietlispach F, Wijesinghe N, Wood D et al. Current balloon - expandable transcatheter heart valve and delivery systems. Catheter Cardiovasc Interv 2010; 75: 295–300.
  31. Rodes-Cabau J, Delarochelliere R, Dumont E. First - in - man transcatheter aortic valve implantation of a 20-mm edwards SAPIEN XT valve: One step forward for the treatment of patients with severe aortic stenosis and small aortic annulus. Catheter Cardiovasc Interv 2011.
  32. Mussardo M, Latib A, Chieffo A et al. Periprocedural and short - term outcomes of transfemoral transcatheter aortic valve implantation with the Sapien XT as compared with the Edwards Sapien valve. JACC Cardiovasc Interv 2011; 4: 743–50.
  33. Chen W, Schoen F.J., Levy R.J. Mechanism of efficacy of 2-amino oleic acid for inhibition of calcification of glutaraldehyde - pretreated porcine bioprosthetic heart valves. Circulation 1994; 90: 323–9.
  34. Vavuranakis M, Vrachatis D.A., Toutouzas K et al. Successful percutaneous aortic valve implantation via a stenotic left subclavian artery access. Heart Vessels 2010; 25: 359–62.
  35. Munoz-Garcia A.J., Alonso-Briales J.H., Such-Martinez M, Hernandez-Garcia J.M. Left subclavian artery approach to CoreValve aortic prosthesis implantation. Rev Esp Cardiol 2010; 63: 121–2.
  36. Ruge H, Lange R, Bleiziffer S et al. First successful aortic valve implantation with the CoreValve ReValving System via right subclavian artery access: a case report. Heart Surg Forum 2008; 11: E323–4.
  37. Moynagh A.M., Scott D.J., Baumbach A et al. UK CoreValve Collaborative. CoreValve transcatheter aortic valve implantation via the subclavian artery: comparison with the transfemoral approach. J Am Coll Cardiol 2011; 57: 634–5.
  38. Mouillet G, Desgranges P, Teiger E. Transcatheter aortic valve implantation when classical access routes are unavailable. Catheter Cardiovasc Interv 2011; 78: 1004–7.
  39. Sarkar K, Ussia G.P., Tamburino C. Transcatheter aortic valve implantation for severe aortic regurgitation in a stentless bioprosthetic valve with the core valve revalving system - technical tips and role of the Accutrak system. Catheter Cardiovasc Interv 2011; 78: 485–90.
  40. Fassl J, Walther T, Groesdonk H.V. et al. Anesthesia management for transapical transcatheter aortic valve implantation: a case series. J Cardiothorac Vasc Anesth 2009; 23: 286–91.
  41. Cockburn J, de Belder A, Brooks M et al. Large calibre arterial access device closure for percutaneous aortic valve interventions: use of the prostar system in 118 cases. Catheter Cardiovasc Interv 2011.
  42. Kahlert P, Eggebrecht H, Erbel R, Sack S. A modified preclosure technique after percutaneous aortic valve replacement. Catheter Cardiovasc Interv 2008; 72: 877–84.
  43. Leon M.B., Piazza N, Nikolsky E et al. Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. Eur Heart J 2011; 32: 205–17.
  44. Leon M.B., Piazza N, Nikolsky E et al. Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. J Am Coll Cardiol 2011; 57: 253–69.
  45. Piazza N, Cutlip D.E., Onuma Y et al. Clinical endpoints in transcatheter aortic valve implantation: a call to ARC for standardised definitions. EuroIntervention 2009; 5: 29–31.
  46. Piazza N, Onuma Y, de Jaegere P, Serruys P.W. Guidelines for reporting mortality and morbidity after cardiac valve interventions – need for a reappraisal? Ann Thorac Surg 2009; 87: 357–8; discussion 359–60.
  47. Thomas M, Wendler O. Transcatheter aortic valve implantation (TAVI): how to interpret the data and what data is required? EuroIntervention 2009; 5: 25–7.
  48. Haworth P, Behan M, Khawaja M et al. Predictors for permanent pacing after transcatheter aortic valve implantation. Catheter Cardiovasc Interv 2010; 76: 751–6.
  49. Abdel-Wahab M, Zahn R, Horack M et al. German transcatheter aortic valve interventions registry investigators. Aortic regurgitation after transcatheter aortic valve implantation: incidence and early outcome. Results from the German transcatheter aortic valve interventions registry. Heart 2011; 97: 899–906.
  50. Bleiziffer S, Ruge H, Hörer J et al. Predictors for new - onset complete heart block after transcatheter aortic valve implantation. JACC Cardiovasc Interv 2010; 3: 524–30.
  51. Motloch L.J., Reda S, Rottlaender D et al. Postprocedural atrial fibrillation after transcatheter aortic valve implantation versus surgical aortic valve replacement. Ann Thorac Surg 2012; 93: 124–31.
  52. Saia F, Marrozzini C, Marzocchi A. Displacement of calcium nodules of the native valve as a possible cause of left main occlusion following transcatheter aortic valve implantation. J Invasive Cardiol 2011; 23: E106–9.
  53. Bartorelli A.L., Andreini D, Sisillo E et al. Left main coronary artery occlusion after percutaneous aortic valve implantation. Ann Thorac Surg 2010; 89: 953–5.
  54. Webb J.G., Pasupati S, Humphries K et al. Percutaneous transarterial aortic valve replacement in selected high - risk patients with aortic stenosis. Circulation 2007; 116: 755–63.
  55. Virmani R, Bonan R, Nakazawa G et al. Accumulation of worldwide experience with postmortem studies of transcatheter aortic valve implantation – what should we be avoiding? In: Serruys P, Piazza N, Cribier A et al. Transcatheter aortic valve implantation: Tips and tricks to avoid failure. New York: Informa Healthcare 2011: 18–39.
  56. Tay E.L., Gurvitch R, Wijeysinghe N et al. Valve thrombosis after transcatheter heart valve implantation. EuroIntervention 2011; 7: 170–1.
  57. Smith C.R., Leon M.B., Mack M.J. et al. PARTNER Trial Investigators. Transcatheter versus surgical aortic - valve replacement in high - risk patients. N Engl J Med 2011; 364: 2187–98.
  58. Wong D.R., Boone R.H., Thompson C.R. et al. Mitral valve injury late after transcatheter aortic valve implantation. J Thorac Cardiovasc Surg 2009; 137: 1547–9.
  59. Webb J.G., Altwegg L, Boone R.H. et al. Transcatheter aortic valve implantation: impact on clinical and valve - related outcomes. Circulation 2009; 119: 3009–16.
  60. Rodés-Cabau J, Webb J.G., Cheung A et al. Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk: acute and late outcomes of the multicenter Canadian experience. J Am Coll Cardiol 2010; 55: 1080–90.
  61. Thomas M, Schymik G, Walther T et al. One - year outcomes of cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) registry: the European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation 2011; 124: 425–33.
  62. Leon M.B., Smith C.R., Mack M et al. PARTNER Trial Investigators. Transcatheter aortic - valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010; 363: 1597–607.
  63. Tay E.L., Gurvitch R, Wijesinghe N et al. A high - risk period for cerebrovascular events exists after transcatheter aortic valve implantation. JACC Cardiovasc Interv 2011; 4: 1290–7.
  64. Rodés-Cabau J, Dumont E, Boone R.H. et al. Cerebral embolism following transcatheter aortic valve implantation: comparison of transfemoral and transapical approaches. J Am Coll Cardiol 2011; 57: 18–28.
  65. Arnold M, Schulz-Heise S, Achenbach S et al. Embolic cerebral insults after transapical aortic valve implantation detected by magnetic resonance imaging. JACC Cardiovasc Interv 2010; 3: 1126–32.
  66. Fairbairn T.A., Mather A.N., Bijsterveld P et al. Diffusion - weighted MRI determined cerebral embolic infarction following transcatheter aortic valve implantation: assessment of predictive risk factors and the relationship to subsequent health status. Heart 2012; 98: 18–23.
  67. Tchetche D, Dumonteil N, Sauguet A et al. Thirty - day outcome and vascular complications after transarterial aortic valve implantation using both Edwards Sapien and Medtronic CoreValve bioprostheses in a mixed population. EuroIntervention 2010; 5: 659–65.
  68. Van Mieghem N.M., Nuis R.J., Piazza N et al. Vascular complications with transcatheter aortic valve implantation using the 18 Fr Medtronic CoreValve System: the Rotterdam experience. EuroIntervention 2010; 5: 673–9.
  69. Ducrocq G, Francis F, Serfaty J.M. et al. Vascular complications of transfemoral aortic valve implantation with the Edwards SAPIEN prosthesis: incidence and impact on outcome. EuroIntervention 2010; 5: 666–72.
  70. Kahlert P, Al-Rashid F, Weber M et al. Vascular access site complications after percutaneous transfemoral aortic valve implantation. Herz 2009; 34: 398–408.
  71. Nuis R.J., Van Mieghem N.M., Tzikas A et al. Frequency, determinants, and prognostic effects of acute kidney injury and red blood cell transfusion in patients undergoing transcatheter aortic valve implantation. Catheter Cardiovasc Interv 2011; 77: 881–9.
  72. Tamburino C, Capodanno D, Ramondo A et al. Incidence and predictors of early and late mortality after transcatheter aortic valve implantation in 663 patients with severe aortic stenosis. Circulation 2011; 123: 299–308.
  73. Bosmans J.M., Kefer J, De Bruyne B et al. Belgian TAVI Registry Participants. Procedural, 30-day and one year outcome following CoreValve or Edwards transcatheter aortic valve implantation: results of the Belgian national registry. Interact Cardiovasc Thorac Surg 2011; 12: 762–7.
  74. Eltchaninoff H, Prat A, Gilard M et al. Transcatheter aortic valve implantation: early results of the FRANCE (FRench Aortic National CoreValve and Edwards) registry. Eur Heart J 2011; 32: 191–7.
  75. Grube E, Buellesfeld L, Mueller R et al. Progress and Current Status of Percutaneous Aortic Valve Replacement: Results of Three Device Generations of the CoreValve Revalving System. Circ Cardiovasc Inter 2008; 1: 167–75.
  76. Gurvitch R, Wood D.A., Tay E.L. et al. Transcatheter aortic valve implantation: durability of clinical and hemodynamic outcomes beyond 3 years in a large patient cohort. Circulation 2010; 122: 1319–27.
  77. Thomas M, Schymik G, Walther T et al. Thirty - day results of the SAPIEN aortic Bioprosthesis European Outcome (SOURCE) Registry: A European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation 2010; 122: 62–9.
  78. Walther T, Kempfert J, Rastan A et al. Transapical aortic valve implantation at 3 years. J Thorac Cardiovasc Surg 2012; 143: 326–31.
  79. Zahn R, Gerckens U, Grube E et al. German Transcatheter Aortic Valve Interventions-Registry Investigators. Transcatheter aortic valve implantation: first results from a multi - centre real - world registry. Eur Heart J 2011; 32: 198–204.
  80. Makkar R.R. Two-Year Outcomes of Transcatheter Aortic Valve Replacement (TAVR), in “Inoperable” Patients With Severe Aortic Stenosis: The PARTNER Trial. San Francisco, CA, USA: Transcatheter Cardiovascular Therapeutics (TCT) 2011.
  81. Reynolds M.R., Magnuson E.A., Lei Y et al. Placement of Aortic Transcatheter Valves (PARTNER) Investigators. Health-Related Quality of Life After Transcatheter Aortic Valve Replacement in Inoperable Patients With Severe Aortic Stenosis. Circulation 2011; 124: 1964–72.
  82. Reynolds M. Lifetime cost effectiveness of implantation compared with standard care in inoperable patients: results from the PARTNER trial (Cohort B). New Orleans, LA, USA: American Heart Association (AHA) 2011.
  83. Cohen D. Health-Related Quality of Life After Transcatheter vs. Surgical Aortic Valve Replacement in High-Risk Patients With Severe Aortic Stenosis - Results From The PARTNER Trial (Cohort A) Transcatheter Cardiovascular Therapeutics (TCT). San Francisco, California 2011.
  84. Clavel M.A., Webb J.G., Pibarot P et al. Comparison of the hemodynamic performance of percutaneous and surgical bioprostheses for the treatment of severe aortic stenosis. J Am Coll Cardiol 2009; 53:1883–91.
  85. Reynolds M. Cost Effectiveness of Transcatheter Aortic Valve Replacement Compared With Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis: Results from The PARTNER Trial (Cohort A). Transcatheter Cardiovascular Therapeutics (TCT). San Francisco, California 2011.
  86. Piazza N, van Gameren M, Jüni P et al. A comparison of patient characteristics and 30-day mortality outcomes after transcatheter aortic valve implantation and surgical aortic valve replacement for the treatment of aortic stenosis: a two - centre study. EuroIntervention 2009; 5: 580–8.
  87. Clavel M.A., Webb J.G., Rodés-Cabau J et al. Comparison between transcatheter and surgical prosthetic valve implantation in patients with severe aortic stenosis and reduced left ventricular ejection fraction. Circulation 2010; 122: 1928–36.
  88. Thourani V.H., Ailawadi G, Szeto W.Y. et al. Outcomes of surgical aortic valve replacement in high - risk patients: a multiinstitutional study. Ann Thorac Surg 2011; 91: 49–55; discussion 55–6.
  89. Böning A, Lutter G, Mrowczynski W et al. Octogenarians undergoing combined aortic valve replacement and myocardial revascularization: perioperative mortality and medium - term survival. Thorac Cardiovasc Surg 2010; 58: 159–63.
  90. Wijesinghe N, Ye J, Rodés-Cabau J et al. Transcatheter aortic valve implantation in patients with bicuspid aortic valve stenosis. JACC Cardiovasc Interv 2010; 3: 1122–5.
  91. Chiam P.T., Chao V.T., Tan S.Y. et al. Percutaneous transcatheter heart valve implantation in a bicuspid aortic valve. JACC Cardiovasc Interv 2010; 3: 559–61.
  92. Raja Y, Holloway B, Doshi S.N. Symmetrical expansion of an Edwards Sapien valve in a congenitally bicuspid aortic valve. Heart 2011; 97: 1113.
  93. Macdonald S. New embolic protection devices: a review. J Cardiovasc Surg (Torino) 2011; 52: 821–7.
  94. Lange R, Bleiziffer S, Mazzitelli D et al. Improvements in transcatheter aortic valve implantation outcomes in lower surgical risk patients: a glimpse into the future. J Am Coll Cardiol 2012; 59: 280–7.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО "Консилиум Медикум", 2013

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».